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Abstract 
The case was a 67-year-old male who visited our hospital with a major complaint of 
macroscopic hematuria. A bladder tumor was found. When a transurethral resection of 
the bladder tumor was performed, the histopathological diagnosis was neuroendocrine 
bladder cancer. After chemotherapy with cisplatin and etoposide a partial shrinkage of 
the tumor was observed; however, the patient expired 7 months after the first visit. 
 
Introduction 
Primary neuroendocrine cancer of the bladder is a rare histological occurrence, 
constituting 0.48–1% of all bladder cancers. The 5-year survival rate is around 8% and the 
prognosis is extremely unfavorable. Due to the morphology of the tumor, treatments 
based on small cell lung cancer have been performed. In this study, we treated a case in 
which chemotherapy was performed with cisplatin (CDDP) and etoposide (VP-16) for 
neuroendocrine cancer that occurred in the bladder; here, we report the results. 
Case Report 
Our patient was a 67-year-old male with a major complaint of macroscopic hematuria. His previous 
history included a traumatic brain hemorrhage at the age of 60 years and stomach cancer at the age of 
64 years. He had no family history in particular.  
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Current Medical History 
In February 2009, the patient noticed blood in his urine and visited our department. A cystoscopy 
revealed a nodular tumor on the right bladder wall. An MRI and bone scintigraphy revealed metastasis 
to both external iliac lymph nodes, resulting in a diagnosis of clinical stage T3bN2M0. In March 2009, 
the patient was hospitalized for the purpose of undergoing a transurethral resection of the bladder 
tumor (TUR-Bt). 
Laboratory Data at the Time of Admission 
Hematological values: RBC 361/μl, WBC 7,600/μl, Hb 11.7 g/dl, Plt 18.8 × 10
4/μl. 
Biochemistry: Alb 4.5 g/dl, TP 7.0 g/dl, T-bil 0.5 mg/dl, AST 16 IU/l, ALT 12 IU/l, ALP 263 IU/l, 
LDH 178 IU/l, BUN 16 mg/dl, Cre 0.84 mg/dl, Na 139 mEq/l, K 4.7 mEq/l, Cl 102 mEq/l, CRP 0.07 g/dl. 
Urinary analysis: pH 5.5, RBC >51/hpf, WBC 11–20/hpf, protein (2+), glucose (–). 
Urinary cytology: class IIIb. 
Image Findings 
Simple pelvic MRI revealed a high basic tumorous lesion with low signals for T1WI, high signals for 
T2WI, and a diameter of 4 cm on the right bladder wall, and invasion outside the wall was observed. In 
the external iliac artery regions on both sides, enlarged lymph nodes with a diameter of 1.5 cm were 
observed. No obvious distal metastasis was detected by bone scintigraphy and thoracic pelvic CT.  
Post-Admission Course 
In March 2009, a TUR-BT was immediately performed for the purpose of obtaining a pathological 
diagnosis. In the histopathological findings, there were a number of large and small solid alveoli of 
atypical cells accompanied by infiltrative growth into the interstitium. The atypical cells had a high N/C 
ratio and rough chromatin, and the neoplastic alveoli also suggested differentiation into the 
neuroendocrine system (fig. 1a). When immunohistological staining was performed, the tumor cells 
were partially positive for CD56 and chromogranin A and negative for synaptophysin (fig. 1b). Based on 
the morphology and the results of immunohistological staining, the patient was diagnosed with 
neuroendocrine cancer. 
Post-Operative Course 
In June 2009, the patient was hospitalized for the purpose of undergoing additional treatment. The 
NSE upon admission was 260 ng/ml. A positron emission tomography-computed tomography (PET-
CT) performed before chemotherapy revealed metastasis to the liver, bones, and lymph nodes (fig. 2). 
Based on the protocol for small cell lung cancer, chemotherapy with cisplatin (CDDP) and etoposide 
(VP-16) was performed along with PE therapy (P: 80 mg/body, E: 100 mg/body). The NSE after 
completing the first course declined to 9.1 ng/ml and CT also revealed tumor shrinkage (fig. 3). 
However, before implementing the second course, the patient’s systemic condition deteriorated, and in 
August 2009, the patient expired due to multiple systemic metastases. 
Discussion 
Since first being reported by Cramer et al. in 1981 [1], neuroendocrine bladder cancer 
has often been reported as primary small cell cancer of the bladder. Histologically, it is 
believed that this condition exhibits a similar histological appearance as small cell lung 
cancer, where the tumor cells are small, the nuclei are rich in chromatin and are circular 
or spindle-shaped, and tumor cells with scarce cytoplasm solidly proliferate. For 
immunostaining, CD56, synaptophysin, and chromogranin A are used. In this study,  
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CD56 and chromogranin A were shown to be partially positive. The case in this study 
involved a high-grade neuroendocrine cancer according to the World Health 
Organization classification, and using the classifications of lung cancer, many parts had 
morphologies equivalent to those of small cell cancer, while some parts exhibited 
morphologies of large cell cancer. 
Blomjous et al. [2] have reported that primary neuroendocrine cancer of the bladder 
constitutes approximately 0.48% of all bladder tumors in autopsy cases. At the time of 
diagnosis, primary neuroendocrine cancer of the bladder is detected as an advanced 
cancer occurring in T3 and T4 in 70% and 16.3% of cases, respectively. In addition, the 5-
year survival rate has been reported to be 8.1–19%, and the prognosis is extremely 
unfavorable [2, 3]. In our present case, too, the cancer progressed rapidly and resulted in 
death 6 months after diagnosis. 
Regarding treatment, multimodality therapy combining surgical therapy and 
chemotherapy/radiation therapy is often implemented; however, this is not yet an 
established therapy. Based on cases of small cell lung cancer, chemotherapy is mainly 
performed with PE therapy using a combination of cisplatin (CDDP) and etoposide (VP-
16), and there are reports in which the prognosis was improved [4]. In this study, we also 
performed PE therapy based on small cell lung cancer and observed a decrease in the NSE 
value and a shrinkage of the tumor on CT images. 
As primary neuroendocrine cancer of the bladder progresses rapidly, we believe that it 
is important to select multimodality therapy via early detection. 
 
 
 
 
 
Fig. 1. a Hematoxylin-eosin stain (×400). b CD56 (×400). 
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Fig. 2. PET-CT. a Liver. b, c Bone. d Lymph node metastases. 
 
 
Fig. 3. CT of abdomen. a, c Before chemotherapy. b, d After chemotherapy. 
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